Chemotherapy of human immunodeficiency virus (HIV) infection: anti-HIV agents targeted at early stages in the virus replicative cycle

Biomed Pharmacother. 1996;50(5):207-15. doi: 10.1016/0753-3322(96)87660-8.


Several compounds have been identified that inhibit an early stage in the replicative cycle of the human immunodeficiency virus (HIV): i) virus adsorption: polysulfates, polysulfonates, polycarboxylates, polyphosphates, and polyoxometalates; or ii) virus-cell fusion: plant lectins, negatively charged albumins and betulinic acid derivatives; iii) virus fusion/uncoating: bicyclam derivatives; iv) reverse transcription: dideoxynucleoside analogues, acyclic nucleoside phosphonates and non-nucleoside reverse transcriptase inhibitors. In principle, HIV may develop resistance to any of these specific anti-HIV agents. However, virus breakthrough can be completely prevented if these agents, alone or in combination, are added to the HIV-infected cells from the beginning at sufficiently high ('knock-out') concentrations.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antiviral Agents / pharmacology*
  • Antiviral Agents / therapeutic use
  • Drug Resistance, Microbial
  • HIV / drug effects
  • HIV / genetics
  • HIV / physiology*
  • HIV Infections / drug therapy*
  • Humans
  • Transcription, Genetic / drug effects
  • Virus Replication / drug effects*


  • Antiviral Agents